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A Medical Research Council trial of two radiotherapy doses in the
treatment of grades 3 and 4 astrocytoma
N.M. Bleehen & S.P. Stenning on behalf of the Medical Research Council Brain Tumour
Working Party*
Summary A total of 474 adult patients with malignant glioma (astrocytoma) grade 3 or 4 were randomised
into an MRC study (BR2) comparing 45 Gy (in 20 fractions over 4 weeks) with 60 Gy (in 30 fractions over 6
weeks) of radiotherapy given post-operatively. Using 2:1 randomisation, 318 patients were allocated the 60 Gy
course and 156 the 45 Gy course. Adjuvant chemotherapy was not given. The results show that a 60 Gy course
produces a modest lengthening of progression-free and overall survival. They suggest a statistically significant
prolongation of median survival from 9 months in the 45 Gy group to 12 months in the 60 Gy group (hazard
ratio = 0.75, x2 = 7.36, d.f. = 1, P = 0.007). Over 80% of patients reported no morbidity from the radio-
therapy, and there was no evidence ofincreased short-term morbidity in the higher dose group. Late morbidity
was not assessed. A prognostic index defined in a previous MRC study was validated in this new cohort. It
identifies a group of patients (20% of the total) with a 2 year survival rate of 28% (95% confidence interval
19% to 38%). It was apparent that the survival advantage to the higher dose was maintained even in the
poorest prognostic groups defined by this index.
Although post-operative radiotherapy has been shown to
improve survival in patients with high grade supratentorial
astrocytoma (Walker et al., 1978), the optimum radiation
dose has not been established. In 1982 when this randomised
trial was proposed the tendency in the UK was to use a dose
in the region of 45 Gy in 20 fractions over 4 weeks, as in the
previous Medical Research Council study of misonidazole
(MRC, 1983). However in the US particularly, a higher dose
of 60 Gy in 30 fractions over 6 weeks was often standard.
The accumulated evidence at that time that a higher dose
improved survival came from retrospective analyses of
several large series using different doses (Walker et al., 1979;
Salazar et al., 1979) and not from randomised trials. Thus
there was no clear evidence as to the optimum dose in the
post-operative treatment of such patients.
In April 1983, the MRC Brain Tumour Working Party
initiated a multicentre study comparing these two radio-
therapy doses in the treatment of adult patients with grade 3
and 4 supratentorial astrocytoma. The results of this study,
and an independent evaluation of the prognostic index deriv-
ed from the previous study (MRC, 1983), are presented here.
Design
The trial aimed to compare the effects of post-operative
radiotherapy at two dose levels - 45 Gy and 60 Gy total dose
- in the treatment of adult patients with grade 3 or 4
supratentorial astrocytoma with respect to time to clinical
deterioration and overall survival.
Following surgery, patients satisfying the eligibility criteria
below were randomised to treatment by a telephone call to
the MRC Cancer Trials Office, with the exception of one
overseas centre where sealed envelopes were provided. Ran-
Correspondence: N.M. Bleehen, MRC Clinical Oncology and Radio-
therapeutics Unit, MRC Centre, Hills Road, Cambridge CB2 2QH,
UK.
*Members: R.O. Barnard, N.M. Bleehen (chairnan), M. Brada, J.D.
Bradshaw, T.B. Brewin, A. Gregor, J.M. Henk, H.F. Hope-Stone,
N. Howard, V. Levin, A.R. Lyons, D.S. Murrell, P.M. Quilty, R.
Rampling, R.I. Rothwell, P.F. Salaman, C.L. Scholtz, J.S. Scott,
L.F.N. Senanayake, B. Southcott, S.P. Stenning (statistician), J.
Stone, H.M. Sultana, C.S. Treip, P.L.C. Xavier.
R.O. Barnard, C.L. Scholtz and C.S. Treip formed the pathology
reference panel. Data management was carried out by J.B. Whaley at
the MRC Cancer Trials Office.
Received 21 November 1990; and in revised form 6 June 1991.
domisation, stratified by participating centre, was planned
such that two out of every three patients were allocated the
60 Gy course to allow accumulation of experience with the
higher dose and a more precise estimate of its efficacy. The
trial aimed to randomise 400 patients to provide 90% power
to detect (at the 5% significance level) a 10% improvement in
18 month survival that is, from 10% in group 1 to 20% in
group 2.
All data forms were returned to the MRC Cancer Trials
Office in Cambridge where data management, using COM.-
PACT (Chilvers et al., 1988), was carried out and from where
the histology review was coordinated. The main endpoint
was survival time which was taken from the data of random-
isation. Time to clinical deterioration was also measured,
with deterioration in neurological status accepted as evidence
of tumour progression.
The eligibility criteria for the trial were as follows:
(1) Pathologically proven supratentorial astrocytoma
grade 3 or 4, including astrocytoma with evidence of
anaplasia, glioblastoma multiforme and giant-celled
glioblastoma.
(2) Age between the 18th and 70th birthday on the day
of entry to the study.
(3) No previous definitive treatment had been given for
the disease apart from aspiration, biopsy or attempt-
ed surgical removal of the tumour, corticosteroids,
anticonvulsants or diuretics.
(4) Radiotherapy could commence within 6 weeks of
neurosurgery.
(5) The patient's neurological and mental function was
not so seriously impaired as to make radiotherapy
undesirable.
(6) Patients had no other previous or concurrent malig-
nant disease (except basal or squamous cell carcin-
oma of the skin), and no other serious condition
likely to prejudice treatment with radiotherapy or to
complicate assessment of progress.
(7) Adequate follow-up of patients after treatment was
considered feasible.
Histology review
Patients were considered eligible for the study only if the
original diagnosis of grade 3 or 4 astrocytoma could be
confirmed by the pathology reference panel. Thus, for every
patient randomised, slides or blocks of the tumour were
requested to be sent initially to the MRC Cancer Trials
Office. The material was then reviewed, independently, by a
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panel of three reference pathologists - each blind to the
allocated treatment - who were asked to grade the tumour
and state whether or not they considered the patient eligible
for the study on histological grounds. In the case of disagree-
ment over eligibility, the majority verdict of the panel was
taken.
Radiotherapy
Radiotherapy was scheduled to commence not later than 6
weeks after neurosurgery, with a recommendation that it
began within 3 weeks.
In group 1, megavoltage radiotherapy was planned to give
a minimum tumour dose of 45 Gy in 20 fractions of 2.25 Gy.
The treatment was to be given 5 days a week for 4 weeks to
a volume that encompassed all known and potential tumour.
In group 2, the total dose of 60 Gy was to be given in two
immediately consecutive series. The initial 40 Gy was given to
a volume similar to group 1, in 20 fractions of 2 Gy over 4
4 weeks. Immediately following this, a dose of 20 Gy in 10
fractions over 2 weeks was to be given, with the target
volume reduced to encompass the defined tumour volume
together with a 1 cm margin around it.
Adjuvant chemotherapy was not employed, but treatment
at relapse was at the clinician's discretion.
Statistical methods
Survival curves were calculated using the Kaplan-Meier
method, and the overall differences in survival curves
examined using the logrank test (Peto et al., 1977). All
comparisons of treatment effect were carried out on an
'intention to treat' basis. To estimate the improvement in
median survival due to treatment after adjusting for prognos-
tic factors, the hazard ratios was used as an estimate of the
ratio of median survival times (Freedman, 1982). Cox's pro-
portional hazards regression model (Tibshirani, 1982) was
used to adjust for the influence of prognostic factors when
assessing treatment effect.
Results
Between April 1983 and September 1988, 474 patients (74
more than the target recruitment) were randomised into the
study from 15 centres in the UK and one in South Africa
(Table I). The pathology reference panel ruled 31 patients
ineligible on the basis of incorrect histology (12 in group 1
and 19 in group 2). Since the pathology review was blind to
treatment assignment, these patients were excluded from this
report. Otherwise, all patients thought eligible at the time
of randomisation were included in the analysis. Thus 443
Table I Participating centres and patient numbers
Centre No. patients randomised
Addenbrookes Hospital, Cambridge 147
Charing Cross, London 5
Cookridge Hospital, Leeds 29
Groote Schuur, Cape Town 17
The London Hospital 25
Ninewells Hospital, Dundee 2
Oldchurch Hospital, Romford 4
Princess Royal, Hull 11
Royal Free, London 23
Royal Marsden, Sutton 10
Royal Sussex County Hospital, Brighton 20
Royal Victorial Hospital, Belfast 44
Velindre Hospital, Cardiff 77
Western General, Edinburgh 7
Western Infirmary, Glasgow 19
Weston Park Hospital, Sheffield 34
Total 474
patients - 144 allocated 45 Gy and 299, 60 Gy are included.
The minimum follow-up time amongst these patients is 14
months.
Pre-radiotherapy characteristics
Table II shows the pre-treatment characteristics of these 443
patients by their allocated treatment. The treatment groups
are well balanced with respect to most of these characteris-
tics, although there is some imbalance in the age distribu-
tions. The effect of this imbalance on the assessment of
treatment efficacy is discussed later.
Treatment
Table III shows the extent of deviations from the protocol
specified radiotherapy. 'Exact adherence' is defined as a dose
of 45 Gy in 20 fractions over 4 to 5 weeks in group 1, and a
total dose of 60 Gy in 30 fractions over 6 to 7 weeks in
group 2.
A 'major deviation' was defined as a total dose in excess of
5 Gy more or less than the protocol specifications. These
occurred mainly when treatment was terminated early
because of the patients deteriorating condition and included
one patient in group 1 and three in group 2 who were
considered too ill to receive any radiotherapy.
Minor deviations therefore comprised small changes in
dose or fractionation, or delays in completing radiotherapy
that were mainly a result of administrative problems, holi-
days or machine breakdown.
Overall exact compliance was 80%, with little difference in
Table II Pre-treatment characteristics
Allocated treatment
45 Gy 60 Gy
Number (%) Number (%) Total
Age (years)
18-39 21 (15) 47 (16) 68 (15)
40-49 35 (24) 55 (18) 90 (20)
50-59 39 (27) 106 (36) 145 (33)
60-73 49 (34) 91 (30) 140 (32)
Extent of neurosurgery
Biopsy/aspiration 66 (46) 126 (42) 192 (43)
Partial removal 55 (38) 124 (41) 179 (41)
Total removal 23 (16) 49 (16) 72 (16)
History of fits
None 107 (74) 214 (72) 321 (72)
Within 3 months of entry 20 (14) 49 (16) 69 (16)
More than 3 months before 17 (12) 35 (12) 52 (12)
entry
Not known 1 1
Pre-radiotherapy anticonvulsant
therapy
No 64 (44) 146 (49) 210 (47)
Yes 79 (56) 151 (51) 230 (53)
Not known 1 2 3
Pre-radiotherapy corticosteroid
dosage (mg d-')
None 18 (13) 50 (17) 68 (15)
1-3 21 (14) 30(10) 51 (12)
4-8 67 (47) 155 (52) 222 (50)
9 + 37 (26) 62 (21) 99 (23)
Not known 1 2 3
Histological grade
Grade 3 45 (31) 102 (34) 147 (33)
Grade 3/4 9 (6) 15 (5) 24 (5)
Grade 4 90 (62) 182 (61) 272 (61)
Pre-radiotherapy WHO
performance status
0 17 (12) 41 (14) 58 (13)
1 54 (38) 120 (40) 174 (40)
2 43 (30) 80 (27) 123 (27)
3 28 (19) 53 (18) 81 (18)
4 2 (1) 5 (2) 7 (2)
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Table III Compliance with protocol radiotherapy
Allocated treatment
45 Gy 60 Gy
Protocol complicance Nwnber (%) Number (%) Total
Exact adherence 124 (86) 232 (78) 356 (80)
Minor deviations 9 (6) 36 (12) 45 (10)
Major deviations 11 (8) 31 (10) 42 (9)
Total 144 299 443
the proportion of major deviations occurring in the two
treatment groups.
Side effects reported at the end of treatment are described
in Table IV. Eighty-three per cent of patients in group 1 and
81% of those in group 2 reported none. There were no major
differences in the incidence of side effects between the two
treatment groups: nausea and vomiting being the only one
reported in more than 5% of cases. Long-term morbidity was
not assessed.
Neurological and clinicalperformance status
Neurological status on the five point MRC scale (see Appen-
dix 1), and clinical performance status on the WHO scale
(see Appendix 1) were recorded immediately before and after
radiotherapy, allowing an assessment of the short-term effect
of the treatment.
On the WHO scale, 26% of patients improved by at least
one point during radiotherapy. Fifty per cent were scored the
same before and after treatment, while 24% deteriorated by
at least one point during radiotherapy. The corresponding
figures for neurological status were that 27% improved by at
least one point, 52% remained at the same score and 21%
deteriorated by at least one point. No major differences were
apparent when the two treatment groups were considered
separately.
WHO performance status was also recorded at each visit
during patient follow-up, and this was the only 'quality of
life' measure assessable. The proportion of patients with a
WHO status of 0 or 1 remained fairly constant throughout
the follow-up period. In the 45 Gy group, a minimum of
51% of patients were grade 1 or better at any time. In the
60 Gy group, the minimum proportion was 45%. A slight
trend towards an increase in this proportion in the long term
survivors was apparent in both groups, but the small
numbers of patients remaining alive makes this data unreli-
able.
Survival
Of the 443 patients, 21 remain alive; 5 in group 1 and 16 in
group 2, with follow-up of between 14 and 60 months.
Table IV Side effects oftreatment
Allocated treatment
45 Gy 60 Gy
Side effect Number (%) Number (%) Total
Nausea/vomiting 13 (9) 25 (8) 38 (9)
Cerebral/facial oedema I (1) 6 (2) 7 (2)
Headaches 5 (4) 4 (1) 9 (2)
Fits - - 5 (2) 4 (1)
Tiredness 2 (1) 3 (1) 5 (1)
Rash/itching 2 (1) 3 (1) 5 (1)
Scalp erythema - - 2 (1) 2 -
Oral Thrush 1 (1) 3 (1) 4 (1)
Hypersensitivity to I (1) 1 - 2 -
anticonvulsants
Depression 1 (1) 1 - 2-
Othera 3b (2) 1Oc (3) 13 (3)
'Each side effect seen in only one patient. bBronchopneumonia,
woundbreakdown, hallucinations.CGIbleeding, otitis, visualdeteriora-
tion, chest pain, CVA, lung infection, glycosuria, dizziness, Cushion-
goid, raised ICP.
Figure 1 shows the survival curves by allocated treatment. At
12 months, the survival rates in group 1 and group 2 were
29% and 39% respectively, the corresponding rates at 18
months being 11% and 18% (Table V). The overall differ-
ence in survival just reaches conventional statistical signi-
ficance, (X2LR = 4.06, d.f. = 1, P = 0.04). The hazard ratio
(HR) of 0.81 (95% CI 0.66 to 0.99) indicates a reduction in
the risk of death for those patients receiving the higher dose
which corresponds to a 2 month improvement in median
survival for this group. In fact this may underestimate the
true benefit of the higher dose because of the unfavourable
age distribution noted previously. A further analysis was
carried out adjusting for age in a proportional hazards
regression model. This suggested a somewhat larger differ-
ence (HR = 0.75, 95% CI = 0.61, 0.92; x2 = 7.36, d.f. = 1,
P = 0.007) suggesting an improvement in median survival
time of approximately 3 months (95% CI = 1 to 6 months)
resulting from the higher dose. Other factors known to affect
prognosis - clinical performance status, history of fits and
extent of neurosurgery - were well balanced between the two
treatment groups and adjustment for these factors in addition
to age did not alter further the estimate of treatment effect.
The ability of the longer treatment course to delay time to
first clinical deterioration was found to be of a similar order
to that seen in terms of survival (HR = 0.84, 95% CI = 0.67
to 1.01 unadjusted for prognostic factors, HR = 0.78 (0.62 to
0.94) after adjusting for age) suggesting an improvement in
median deterioration-free time of approximately 2 months.
Prognosticfactors
An analysis of prognostic factors in the previous MRC study
(MRC, 1983) identified age, clinical performance status
before radiotherapy, length of history of fits and extent of
neurosurgery as the only independently important charac-
teristics (MRC, 1990). A prognostic index based on these
four factors (Table VI) was used to divide patients into six
groups of varying prognosis, a low index score indicating a
good prognosis. Applying this index to patients entered into
this study confirmed its value. Figure 2 shows the survival
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Table V Survival rates %
Allocated treatment
Months 45 Gy 60 Gy
0 100 100
6 69 74
12 29 39
18 11 18
24 8 12
30 5 8
36 5 6
No. patients 144 299772 MRC BRAIN TUMOUR WORKING PARTY
Table VI Definition ofprognostic index
Prognosticfactor Category Score
Age (years) <44 0
45-59 6
)60 12
WHO performance status 0-1 0
2 4
3-4 8
Extent of neurosurgery complete resection 0
partial resection 4
biopsy 8
History of fits (months) > 3 0
<3 5
none 10
Prognostic Index = sum of scores for each factor, a low score
indicating a better prognosis.
a)
cn
(U
-1
0 3 6 9 12 15 18 21 24 27 30 33 36
Months from randomisation
Figure 2 Prognostic groups. Index score: 0-10; -O-
11-15; --- 16-20; -*- 21-25; ...... 26-33; O 34-38.
curves for the six prognostic groups. The two 'best' groups
combined comprise just over 20% of the total and have a 2
year survival rate of 28% (95% CI 19%, 38%).
It is clearly of interest to know if the advantage to the
higher dose is maintained in the poorer prognosis patients.
To investigate this, patients were divided into three groups
on the basis of their prognostic index score and a logrank
analysis of treatment effect carried out within each of the
three groups. The problems of subgroup analysis must be
recognised, particularly here where the overall treatment
effect is small, and the chance of obtaining spurious results in
smaller subgroups high. Table VII summarises the results of
these exploratory analyses. A significant improvement in sur-
vival was still apparent in the poorest prognostic group,
which had an overall 2 year survival rate of 3% (X2LR = 5.7,
d.f. = 1, P = 0.02). While noting the limitations of subgroup
analyses mentioned above, this data provides no evidence of
lack of efficacy of the higher dose in the poorest prognosis
patients.
Discussion
Radiation dose
This trial has addressed the important question of the opti-
mum dose of external beam radiotherapy in high grade
gliomas. It has demonstrated that a small but significant
Table VII Analysis of treatment effect by prognostic group
Index score No. patients Hazard Ratio (95% CI)
< 15 92 0.82 (0.51, 1.30)
16-25 175 0.81 (0.58, 1.12)
>26 176 0.71 (0.52, 0.97)
survival gain is achieved when 60 Gy is compared with the
45 Gy dose schedule.
There have been numerous previous reports on the opti-
mum radiation dose (Chang et al., 1983; Onoyoma et al.,
1976; Walker et al., 1979; Salazar et al., 1979; Scanlon &
Taylor, 1979; Rutten et al., 1981). The key report from the
US Brain Tumour Study Group (Walker et al., 1979), analys-
ed the relationship between increasing survival and increasing
doses of radiotherapy on 621 patients entered into three
successive studies. Patients were divided into three groups
with median total doses of 50, 55 or 60 Gy. The median
survival times (MST) were 28, 36 and 42 weeks respectively.
The increase in MST from 50 to 60 Gy was highly significant.
However, it is important to again note that patients were not
randomised, but retrospectively allocated to the three dose
groups.
Salazar et al. (1979) also reviewed 100 patients, grouped
retrospectively, with median doses of 50, 60 and 75 Gy. Each
dose group was analysed in subgroups according to tumour
grade (3 or 4). The study was not randomised and numbers,
particularly in the high dose group, were small. A trend to
improved survival with higher dose was noted. In contrast,
a subsequent joint Radiation Therapy Oncology Group
(RTOG) and Eastern Cooperative Oncology Group (ECOG)
randomised study (Chang et al., 1983) compared 148 patients
allocated 60 Gy given over 6 to 7 weeks whole brain irradia-
tion with 105 given that dose plus a booster dose of 10 Gy to
the tumour volume (in 1-2 further weeks). There were no
differences seen in overall survival between the two groups.
Thus the value of external beam doses higher than 60 Gy
remains in question.
The total radiation dose that may be delivered to brain
tumours is limited by the normal tissue toxicity (Sheline,
1986). Methods of increasing the effective tumour dose with-
out increase in normal tissue damage have been investigated
recently. These include interstitial implantation of removable
high activity sources of iodine-125 (Leibel et al., 1989), or
irridium-192 (Chun et al., 1989); endocavitary intra-operative
cobalt - 60 sources (Kumar et al., 1989), and stereotactic
external beam 'radiosurgery' using a linear accelerator (Hart-
mann et al., 1985). Boron-neutron capture as originally pro-
posed by Sweet (1951), is also under reinvestigation.
Altered fractionation schedules employing multiple daily
fractions have yielded conflicting results (Davis, 1989). In
general, no improvement in survival over conventional treat-
ment was seen. In one study a significant advantage to
multiple daily fractions was reported (Shin et al., 1985) but
the MST in the control group was only 27 weeks, placing the
overall conclusion in some doubt.
Treatment volume
The optimum treatment volume remains uncertain. In this
study an initial volume of most of the supratentorial brain
widely encompassing the tumour was selected. A more close-
ly defined boost volume was then selected in the high dose
group. This practice varied in the other studies discussed
above with the initial treatment ranging from whole brain to
a boost with a 1-2 cm margin around the radiologically
defined tumour. Early work by Concannon et al. (1960)
suggested wide infiltration in high grade gliomas and this has
determined subsequent radiation practice with its emphasis
on whole brain radiation. However, a recent BTCG study
confirmed the efficacy of wide field irradiation followed by a
boost as compared to whole brain irradiation (Shapiro et al.,
1989).
Most recent trends attempting to achieve higher doses have
resulted in reduction of target volumes, but difficulties in
defining that volume remain. Thus when the extent of
tumour and 'oedema' as seen on immediate antemortem CT
examination were related to the post mortem findings, they
were shown to underestimate considerably the extent of the
tumour (Halperin et al., 1989). In a pattern of failure study,
Wallner et al. (1989), concluded that partial brain irradition
was feasible. They observed that 18/32 (56%) of unifocal
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recurrences occurred within 1 cm of the pre-surgery enhanc-
ing tumour edge as seen on CT, and 25/32 (78%) within
2cm. In our present study the protocol defined a tumour
margin of 1 cm in the boost volume. This may have resulted
in some marginal recurrences. The data in the two post
mortem studies are however based on relatively small
numbers.
Adjuvant chemotherapy
The role of adjuvant chemotherapy remains under actiye
investigation but awaits identification of more effective drugs
and combinations than are presently available. In this trial
chemotherapy was only employed when deemed appropriate
on relapse. Only 12 patients in the low-dose group (9%)
received chemotherapy on relapse and 21 (7%) in the higher
dose group. Many groups use adjuvant chemotherapy as part
of the initial treatment strategy. This may confer a small
survival advantage over control non-chemotherapy groups. A
review of published trials (Stenning et al., 1987) suggests the
benefit from addition of a nitrosourea may be of the same
order as that resulting from use of the higher radiotherapy
dose used here. The overall results in this study may there-
fore have been improved if a nitrosourea containing adjuvant
regimen had been employed. In the present MRC high grade
glioma study (MRC/BR5) this role of adjuvant chemother-
apy is being explored.
Prognosticfactors
The importance of prognostic factors in patients with high
grade gliomas has been emphasised in reports from several
groups (Walker et al., 1978; Walker et al., 1980; Chang et al.,
1983; EORTC, 1981; MRC, 1990). These have included age
of patient, performance status, duration of symptoms and
tumour grade. Other less important features are blood group,
pretreatment white cell and platelet counts and level of con-
sciousness after surgery (Green et al., 1983). An analysis of
417 patients in the MRC Brain Tumour Working Party
misonidazole study (MRC/BR1) identified age, clinical per-
formance status, length of history of fits and extent of
surgery as the only independent prognostic variables (MRC,
1990). The predictive value of the index proposed in that
study has been confirmed in the present study (Table VI and
Figure 2). Such an index may be of value in the design of
future study protocols and routine clinical treatment deci-
sions.
It is of interest that the advantage of the higher dose was
maintained in the poorer prognostic group. However, the
short overall median survival time in the latter groups casts
doubt of the value of routine use of such prolonged treat-
ments in such patients.
Conclusions
This trial has demonstrated that a modest progression-free
and overall survival gain is achieved by using 60 Gy as
opposed to 45 Gy in the post-operative treatment of grades 3
and 4 astrocytoma. The estimated gain corresponds to a 3
month increase in median survival time, from 9 months in
patients receiving the lower dose to 12 months in those
receiving the higher dose.
The results of this trial, in conjunction with the prognostic
index, may aid the rational selection of patients for pro-
longed intensive courses of therapy in a disease with such
poor overall survival results.
Appendix 1
MRC neurological status
O= No neurological deficit.
I= Some neurological deficit but function adequate for useful
work.
2= Neurological deficit causing moderate functional impairment
e.g. able to move limb/s only with difficulty, moderate dys-
phasia, moderate paresis, some visual disturbance.
3 = Neurological deficit causing major functional impairment e.g.
inability to move limb/s, gross speech or visual disturbances.
4= No useful function - inability to make conscious responses.
WHO clinical performance status
O= Able to carry out all normal activity without restriction.
I = Restricted in physically strenuous activity, but ambulatory and
able to carry out light work.
2= Ambulatory and capable of all self-care but unable to carry
out any work; up and about more than 50% ofwaking hours.
3 = Capable only of limited self-care; confined to bed or chair
more than 50% of waking hours.
4= Completely disabled; cannot carry out any self-care; totally
confined to bed or chair.
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